Auditing fungal disease in leukemia patients in a tertiary care center: opportunities and challenges for an antifungal stewardship program

References

• Auberger J, Lass-Florl C, Ulmer H, et al. Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol. 2008;88:508–515.
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Ruping MJ, Wisplinghoff H, et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicro Chemother. 2010;65:1466–1471.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood. 2003;101:3365–3372.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91:1068–1075.
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah MR, Grigg A, Downey MT, et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica. 2012;97:459–463.
   PubMed Web of Science ®Google Scholar
• Pagano L, Akova M, Dimopoulos G, et al. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother. 2011;66:i5.
   PubMed Web of Science ®Google Scholar
• Fleming S, Yannakou CK, Haeusler GM, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J. 2014;44:1283–1297.
   PubMed Web of Science ®Google Scholar
• Henden A, Morris K, Truloff N, et al. Incidence and outcomes of invasive fungal disease in adult patients with acute lymphoblastic leukemia treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone: implications for prophylaxis. Leukemia Lymphoma. 2013;54:1329–1331.
   PubMed Web of Science ®Google Scholar
• Mariette C, Tavernier E, Hocquet D, et al. Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study. Leukemia Lymphoma. 2016;58:1–8.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Leguay T, Maertens J, et al. Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia. J Antimicrob Chemother. 2017;72:2359–2367.
   PubMed Web of Science ®Google Scholar
• Stanzani M, Lewis RE, Fiacchini M, et al. A risk prediction score for invasive mold disease in patients with hematological malignancies. PLoS One. 2013;8:e75531.
   PubMed Web of Science ®Google Scholar
• Munoz P, Valerio M, Vena A, et al. Antifungal stewardship in daily practice and health economic implications. Mycoses. 2015;58:14–25.
   PubMed Web of Science ®Google Scholar
• Aguado JM, Silva JT, Bouza E. Conclusion and future perspectives on antifungal stewardship. J Antimicrob Chemother. 2016;71:ii43–ii44.
   PubMed Web of Science ®Google Scholar
• National Centre for Antimicrobial Stewardship. Our Solutions 2017. [cited 2017 Nov 25]. Available from: https://www.ncas-australia.org/our-solutions
   Google Scholar
• Halliday C, Wu QX, James G, et al. Development of a nested qualitative real-time PCR assay to detect Aspergillus species DNA in clinical specimens. J Clin Microbiol. 2005;43:5366–5368.
   PubMed Web of Science ®Google Scholar
• Heng S-C, Chen SCA, Morrissey CO, et al. Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies. Diagnostic Microbio Infect Dis. 2014;79:322–327.
   PubMed Web of Science ®Google Scholar
• Lau A, Chen S, Sorrell T, et al. Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. J Clin Microbio. 2007;45:380–385.
   PubMed Web of Science ®Google Scholar
• Duarte RF, Sanchez-Ortega I, Cuesta I, et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis. 2014;59:1696–1702.
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–1821.
   PubMed Web of Science ®Google Scholar
• National Centre for Antimicrobial Stewardship. National Antimicrobial Prescribing Survey. 2017. [cited 2017 Nov 25]. Available from: https://www.naps.org.au/Default.aspx
   Google Scholar
• James R, Upjohn L, Cotta M, et al. Measuring antimicrobial prescribing quality in Australian hospitals: development and evaluation of a national antimicrobial prescribing survey tool. J Antimicrob Chemother. 2015;70:1912–1918.
   PubMed Web of Science ®Google Scholar
• Barreto JN, Beach CL, Wolf RC, et al. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole. Am J Hematol. 2013;88:283–288.
   PubMed Web of Science ®Google Scholar
• Biehl LM, Vehreschild JJ, Liss B, et al. A cohort study on breakthrough invasive fungal infections in high-risk patients receiving antifungal prophylaxis. J Antimicrob Chemother. 2016;71:2634–2641.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–359.
   PubMed Web of Science ®Google Scholar
• Pazos C, Pontón J, Palacio AD. Contribution of (1→3)-β-d-Glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbio. 2005;43:299–305.
   PubMed Web of Science ®Google Scholar
• Dekkers BG, Bakker M, van der Elst KC, et al. Therapeutic drug monitoring of posaconazole: an update. Curr Fungal Infect Rep. 2016;10:51–61.
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah MR, Cheng A, Morrissey CO, et al. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach. Antimicrob Agents Chemother. 2011;55:1953–1960.
   PubMed Web of Science ®Google Scholar
• Hamdy RF, Zaoutis TE, Seo SK. Antifungal stewardship considerations for adults and pediatrics. Virulence. 2017;8:658.
   PubMed Web of Science ®Google Scholar
• van Hal SJ, Gilroy NM, Morrissey CO, et al. Survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand. Intern Med J. 2014;44:1277–1282.
   PubMed Web of Science ®Google Scholar
• Micallef C, Aliyu SH, Santos R, et al. Introduction of an antifungal stewardship programme targeting high-cost antifungals at a tertiary hospital in Cambridge, England. J Antimicro Chemother. 2015;70:1908–1911.
   PubMed Web of Science ®Google Scholar
• Mondain V, Lieutier F, Hasseine L, et al. A 6-year antifungal stewardship programme in a teaching hospital. Infection. 2013;41:621–628.
   PubMed Web of Science ®Google Scholar
• Mulanovich V, Kontoyiannis DP. Acute myeloid leukemia and the infectious diseases consultant. Leukemia Lymphoma. 2017;15:1–8.
   Google Scholar
• Bartlett A, Goeman E, Vedi A, et al. A pilot study of a computerized decision support system to detect invasive fungal infection in pediatric hematology/oncology patients. Infect Control Hosp Epidemiol. 2015;36:1313–1317.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52:e56–e93.
   PubMed Web of Science ®Google Scholar
• Mellinghoff SC, Panse J, Alakel N, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol. 2018;97:197–207.
   PubMed Web of Science ®Google Scholar
• Maertens J, Marchetti O, Herbrecht R, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant. 2011;46:709–718.
   PubMed Web of Science ®Google Scholar
• Pagano L, Stamouli M, Tumbarello M, et al. Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry. Br J Haematol. 2015;170:434–439.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:11111–11121.
   Web of Science ®Google Scholar
• Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012;120:1570–1580.
   PubMed Web of Science ®Google Scholar
• Pomares H, Arnan M, Sanchez-Ortega I, et al. Invasive fungal infections in AML/MDS patients treated with azacitidine: a risk worth considering antifungal prophylaxis? Mycoses. 2016;59:516–519.
   PubMed Web of Science ®Google Scholar
• Pham AN, Bubalo JS, Lewis JS. 2nd. Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections. Mycoses. 2016;59:226–233.
   PubMed Web of Science ®Google Scholar
• Cumpston A, Caddell R, Shillingburg A, et al. Superior serum concentrations with posaconazole delayed-release tablets compared to suspension formulation in hematological malignancies. Antimicrob Agents Chemother. 2015;59:4424–4428.
   PubMed Web of Science ®Google Scholar
• Tang LA, Marini BL, Benitez L, et al. Risk factors for subtherapeutic levels of posaconazole tablet. J Antimicro Chemother. 2017;72:2902–2905.
   PubMed Web of Science ®Google Scholar
• Miceli MH, Perissinotti AJ, Kauffman CA, et al. Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis. Mycoses. 2015;58:432–436.
   PubMed Web of Science ®Google Scholar
• Urbancic KF, Thursky K, Kong DCM, et al. Antifungal stewardship: developments in the field. Curr Opin Infect Dis. 2018;31:490–498.
   PubMed Web of Science ®Google Scholar
• Ananda-Rajah MR, Slavin MA, Thursky KT. The case for antifungal stewardship. Curr Opin Infect Dis. 2012;25:107–115.
   PubMed Web of Science ®Google Scholar